AccurKardia, a New York-based medical AI software company that specializes in delivering high-quality ECG interpretation software, secured $2.7 million in a seed round.
The funding comes from various investors, including the Popular Impact Fund, an early-stage investment vehicle associated with Popular Inc., as well as other private investors.
This investment will support AccurKardia’s mission to deliver world-class clinical-grade ECG interpretation software to cardiac monitoring companies, thereby expanding access to the benefits of remote cardiac care to millions of patients worldwide.
Furthermore, AccurKardia has been chosen to be a part of Cohort 3 of the Mayo Clinic Platform_Accelerate program. This esteemed program grants AccurKardia access to Mayo Clinic's extensive de-identified datasets, validation frameworks, clinical workflow planning, and mentorship.
Since March 2023, AccurKardia has been leveraging these valuable resources to expedite its research and development efforts, as well as its clinical validation work.
“Given that cardiovascular disease continues to be the leading cause of death worldwide, affecting millions of people, this funding round is key to continuing our journey to bring this technology to market, continue our validation efforts and collaborate with leading cardiology monitoring providers ,” said Juan C. Jiménez, CEO of AccurKardia.
Company: AccurKardia, Inc.
Round: Seed Round
Funding Month: June 2023
Lead Investors: Popular Impact Fund
Company Website: https://www.accurkardia.com/
Software Category: Medical AI Software
About the Company: AccurKardia delivers automated clinical-grade ECG interpretation software to cardiac monitoring companies, thereby expanding access to the benefits of remote cardiac care to millions of patients worldwide.AccurKardia combines proprietary AI and non-AI-based techniques to provide near-real-time ECG analytics in the cloud, on the device, and at the edge.